The visual science of a first-in-class treatment in HoFH.
This excerpt is taken from our 3D animation work for a biopharmaceutical company that developed an FDA-approved orphan drug, aimed at treating the rare genetic disease homozygous familial hypercholesterolemia (HoFH).
This video explores the activity within the body of a person affected with HoFH — explaining the normal and abnormal functions of LDL-C.
Deliverables
3D animations, multiple language videos, 3D illustrations - online, banner & brochure
Brand
Juxtapid (USA) & Lojuxta (EU)
Client
Aegerion Pharmaceuticals
What is
Homozygous Familial Hypercholesterolemia (HoFH)
Familial hypercholesterolemia (FH), an autosomal codominant disease, is characterized by high levels of LDL cholesterol and a high incidence of coronary artery disease (CAD).
Homozygous Familial Hypercholesterolemia, or HoFH, is a rare genetic lipid disorder usually caused by defects in the low-density lipoprotein, or LDL, receptor genes, inherited from both parents, resulting in impaired or total loss of function in the LDL receptor.
references: www.circ.ahajournals.org Article: Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation / J. Ferrieres, MD, MSc; J. Lambert, PhD; S. Lussier-Cacan, PhD; J. Davignon, MD, Msc, aegerion.com
Senior Director Business Development & US Marketing, Rare Disease, Aegerion Pharmaceuticals, Massachusetts, USA
Get in touch and start your creative journey.
Contact UsNext case study
35A Victoria Rd.,
Surbiton, Surrey,
KT6 4JT, UK